WO2002053127A1 - Agents d'inhibition ou de reparation d'affections cutanees causees par la secheresse, et procede d'evaluation de celles-ci - Google Patents
Agents d'inhibition ou de reparation d'affections cutanees causees par la secheresse, et procede d'evaluation de celles-ci Download PDFInfo
- Publication number
- WO2002053127A1 WO2002053127A1 PCT/JP2001/011615 JP0111615W WO02053127A1 WO 2002053127 A1 WO2002053127 A1 WO 2002053127A1 JP 0111615 W JP0111615 W JP 0111615W WO 02053127 A1 WO02053127 A1 WO 02053127A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- glycerin
- crude drug
- betaine
- skin
- external preparation
- Prior art date
Links
- 238000001035 drying Methods 0.000 title claims description 31
- 238000000034 method Methods 0.000 title claims description 17
- 230000037380 skin damage Effects 0.000 title claims description 7
- 230000002401 inhibitory effect Effects 0.000 title 1
- 239000003814 drug Substances 0.000 claims abstract description 62
- 229940079593 drug Drugs 0.000 claims abstract description 61
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims abstract description 48
- 230000014509 gene expression Effects 0.000 claims abstract description 48
- 239000000126 substance Substances 0.000 claims abstract description 47
- 210000002510 keratinocyte Anatomy 0.000 claims abstract description 45
- 101710088660 Filaggrin Proteins 0.000 claims abstract description 42
- 238000002360 preparation method Methods 0.000 claims abstract description 40
- 210000003491 skin Anatomy 0.000 claims abstract description 37
- 230000007423 decrease Effects 0.000 claims abstract description 29
- 229960003237 betaine Drugs 0.000 claims abstract description 25
- 229920005862 polyol Polymers 0.000 claims abstract description 12
- 150000003077 polyols Chemical class 0.000 claims abstract description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 136
- 241000411851 herbal medicine Species 0.000 claims description 71
- 235000011187 glycerol Nutrition 0.000 claims description 68
- -1 2-hydroxyethyl methacryl Chemical group 0.000 claims description 59
- 239000000203 mixture Substances 0.000 claims description 48
- 239000000284 extract Substances 0.000 claims description 41
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 28
- 102100028314 Filaggrin Human genes 0.000 claims description 24
- 241000196324 Embryophyta Species 0.000 claims description 21
- 238000012360 testing method Methods 0.000 claims description 19
- 210000004027 cell Anatomy 0.000 claims description 18
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 17
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 17
- 239000000811 xylitol Substances 0.000 claims description 17
- 235000010447 xylitol Nutrition 0.000 claims description 17
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 17
- 229960002675 xylitol Drugs 0.000 claims description 17
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 16
- 235000010323 ascorbic acid Nutrition 0.000 claims description 15
- 239000011668 ascorbic acid Substances 0.000 claims description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- 238000011156 evaluation Methods 0.000 claims description 14
- VVIUBCNYACGLLV-UHFFFAOYSA-N hypotaurine Chemical compound [NH3+]CCS([O-])=O VVIUBCNYACGLLV-UHFFFAOYSA-N 0.000 claims description 13
- 210000000434 stratum corneum Anatomy 0.000 claims description 13
- 108700041153 Filaggrin Proteins Proteins 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 12
- 230000003078 antioxidant effect Effects 0.000 claims description 11
- 229960005070 ascorbic acid Drugs 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 11
- 239000002537 cosmetic Substances 0.000 claims description 10
- 108010024636 Glutathione Proteins 0.000 claims description 8
- 208000028990 Skin injury Diseases 0.000 claims description 8
- 150000001413 amino acids Chemical class 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 229960003180 glutathione Drugs 0.000 claims description 8
- 239000004386 Erythritol Substances 0.000 claims description 7
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 7
- 241000208690 Hamamelis Species 0.000 claims description 7
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 7
- 235000019414 erythritol Nutrition 0.000 claims description 7
- 229940009714 erythritol Drugs 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 235000011203 Origanum Nutrition 0.000 claims description 6
- 240000000783 Origanum majorana Species 0.000 claims description 6
- 235000011449 Rosa Nutrition 0.000 claims description 6
- 150000005846 sugar alcohols Chemical class 0.000 claims description 6
- 241000208838 Asteraceae Species 0.000 claims description 4
- 235000010663 Lavandula angustifolia Nutrition 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 4
- 230000004888 barrier function Effects 0.000 claims description 4
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 108020004999 messenger RNA Proteins 0.000 claims description 4
- 230000003020 moisturizing effect Effects 0.000 claims description 4
- 241001238072 Achyrocline Species 0.000 claims description 3
- 241000207923 Lamiaceae Species 0.000 claims description 3
- 241001529744 Origanum Species 0.000 claims description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
- 230000000996 additive effect Effects 0.000 claims description 3
- 210000003953 foreskin Anatomy 0.000 claims description 3
- 229960005375 lutein Drugs 0.000 claims description 3
- 235000012680 lutein Nutrition 0.000 claims description 3
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims description 3
- 239000001656 lutein Substances 0.000 claims description 3
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims description 3
- 239000011593 sulfur Substances 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims description 3
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims description 3
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 claims description 2
- ZWVMLYRJXORSEP-UHFFFAOYSA-N 1,2,6-Hexanetriol Chemical compound OCCCCC(O)CO ZWVMLYRJXORSEP-UHFFFAOYSA-N 0.000 claims description 2
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims description 2
- 229940043375 1,5-pentanediol Drugs 0.000 claims description 2
- HVYJSOSGTDINLW-UHFFFAOYSA-N 2-[dimethyl(octadecyl)azaniumyl]acetate Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CC([O-])=O HVYJSOSGTDINLW-UHFFFAOYSA-N 0.000 claims description 2
- KKMIHKCGXQMFEU-UHFFFAOYSA-N 2-[dimethyl(tetradecyl)azaniumyl]acetate Chemical compound CCCCCCCCCCCCCC[N+](C)(C)CC([O-])=O KKMIHKCGXQMFEU-UHFFFAOYSA-N 0.000 claims description 2
- ZKWJQNCOTNUNMF-QXMHVHEDSA-N 2-[dimethyl-[3-[[(z)-octadec-9-enoyl]amino]propyl]azaniumyl]acetate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O ZKWJQNCOTNUNMF-QXMHVHEDSA-N 0.000 claims description 2
- SQXSZTQNKBBYPM-UHFFFAOYSA-N 2-[docosyl(dimethyl)azaniumyl]acetate Chemical compound CCCCCCCCCCCCCCCCCCCCCC[N+](C)(C)CC([O-])=O SQXSZTQNKBBYPM-UHFFFAOYSA-N 0.000 claims description 2
- TYIOVYZMKITKRO-UHFFFAOYSA-N 2-[hexadecyl(dimethyl)azaniumyl]acetate Chemical compound CCCCCCCCCCCCCCCC[N+](C)(C)CC([O-])=O TYIOVYZMKITKRO-UHFFFAOYSA-N 0.000 claims description 2
- 240000000073 Achillea millefolium Species 0.000 claims description 2
- 244000296825 Amygdalus nana Species 0.000 claims description 2
- 235000003840 Amygdalus nana Nutrition 0.000 claims description 2
- 241000737241 Cocos Species 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- 241000208680 Hamamelis mollis Species 0.000 claims description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 2
- 235000010701 Lavanda vera Nutrition 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 235000006297 Origanum majorana Nutrition 0.000 claims description 2
- ALQSHHUCVQOPAS-UHFFFAOYSA-N Pentane-1,5-diol Chemical compound OCCCCCO ALQSHHUCVQOPAS-UHFFFAOYSA-N 0.000 claims description 2
- 235000011432 Prunus Nutrition 0.000 claims description 2
- 244000141698 Prunus lannesiana Species 0.000 claims description 2
- 235000015527 Prunus lannesiana Nutrition 0.000 claims description 2
- 241000207929 Scutellaria Species 0.000 claims description 2
- 240000004534 Scutellaria baicalensis Species 0.000 claims description 2
- 235000017089 Scutellaria baicalensis Nutrition 0.000 claims description 2
- MRUAUOIMASANKQ-UHFFFAOYSA-O carboxymethyl-[3-(dodecanoylamino)propyl]-dimethylazanium Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC(O)=O MRUAUOIMASANKQ-UHFFFAOYSA-O 0.000 claims description 2
- 229940105990 diglycerin Drugs 0.000 claims description 2
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 claims description 2
- 239000001963 growth medium Substances 0.000 claims description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 2
- 229960000367 inositol Drugs 0.000 claims description 2
- 239000000832 lactitol Substances 0.000 claims description 2
- 235000010448 lactitol Nutrition 0.000 claims description 2
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims description 2
- 229960003451 lactitol Drugs 0.000 claims description 2
- 229940075468 lauramidopropyl betaine Drugs 0.000 claims description 2
- 229940094506 lauryl betaine Drugs 0.000 claims description 2
- IZWSFJTYBVKZNK-UHFFFAOYSA-N lauryl sulfobetaine Chemical compound CCCCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O IZWSFJTYBVKZNK-UHFFFAOYSA-N 0.000 claims description 2
- 239000001102 lavandula vera Substances 0.000 claims description 2
- 235000018219 lavender Nutrition 0.000 claims description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 2
- 239000000845 maltitol Substances 0.000 claims description 2
- 235000010449 maltitol Nutrition 0.000 claims description 2
- 229940035436 maltitol Drugs 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 229960001855 mannitol Drugs 0.000 claims description 2
- 239000002207 metabolite Substances 0.000 claims description 2
- DVEKCXOJTLDBFE-UHFFFAOYSA-N n-dodecyl-n,n-dimethylglycinate Chemical compound CCCCCCCCCCCC[N+](C)(C)CC([O-])=O DVEKCXOJTLDBFE-UHFFFAOYSA-N 0.000 claims description 2
- 229920000166 polytrimethylene carbonate Polymers 0.000 claims description 2
- 235000014774 prunus Nutrition 0.000 claims description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 2
- 210000001541 thymus gland Anatomy 0.000 claims description 2
- 229960005150 glycerol Drugs 0.000 claims 3
- 241000722941 Achillea Species 0.000 claims 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 claims 2
- 241001492452 Eysenhardtia Species 0.000 claims 2
- 244000178870 Lavandula angustifolia Species 0.000 claims 2
- NPKLJZUIYWRNMV-UHFFFAOYSA-N 2-[decyl(dimethyl)azaniumyl]acetate Chemical compound CCCCCCCCCC[N+](C)(C)CC([O-])=O NPKLJZUIYWRNMV-UHFFFAOYSA-N 0.000 claims 1
- QWGRWMMWNDWRQN-UHFFFAOYSA-N 2-methylpropane-1,3-diol Chemical compound OCC(C)CO QWGRWMMWNDWRQN-UHFFFAOYSA-N 0.000 claims 1
- 235000007754 Achillea millefolium Nutrition 0.000 claims 1
- 241000349731 Afzelia bipindensis Species 0.000 claims 1
- 235000005078 Chaenomeles speciosa Nutrition 0.000 claims 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 claims 1
- 244000251905 Pseudocydonia sinensis Species 0.000 claims 1
- 235000017831 Pseudocydonia sinensis Nutrition 0.000 claims 1
- 235000012208 gluconic acid Nutrition 0.000 claims 1
- 239000000174 gluconic acid Substances 0.000 claims 1
- 235000008216 herbs Nutrition 0.000 claims 1
- HLERILKGMXJNBU-UHFFFAOYSA-N norvaline betaine Chemical compound CCCC(C([O-])=O)[N+](C)(C)C HLERILKGMXJNBU-UHFFFAOYSA-N 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 abstract description 14
- 239000003963 antioxidant agent Substances 0.000 abstract description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 abstract 1
- 239000007792 gaseous phase Substances 0.000 abstract 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 51
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 51
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 45
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 44
- 239000008213 purified water Substances 0.000 description 42
- 239000000419 plant extract Substances 0.000 description 40
- 238000009472 formulation Methods 0.000 description 39
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 32
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 30
- 239000006071 cream Substances 0.000 description 23
- 229940058015 1,3-butylene glycol Drugs 0.000 description 22
- 235000019437 butane-1,3-diol Nutrition 0.000 description 22
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 22
- 229940032094 squalane Drugs 0.000 description 22
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 21
- 239000003086 colorant Substances 0.000 description 18
- 239000000839 emulsion Substances 0.000 description 16
- 235000019441 ethanol Nutrition 0.000 description 16
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 16
- 229960000735 docosanol Drugs 0.000 description 15
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 14
- MOMKYJPSVWEWPM-UHFFFAOYSA-N 4-(chloromethyl)-2-(4-methylphenyl)-1,3-thiazole Chemical compound C1=CC(C)=CC=C1C1=NC(CCl)=CS1 MOMKYJPSVWEWPM-UHFFFAOYSA-N 0.000 description 13
- QZKRHPLGUJDVAR-UHFFFAOYSA-K EDTA trisodium salt Chemical compound [Na+].[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O QZKRHPLGUJDVAR-UHFFFAOYSA-K 0.000 description 13
- 235000019983 sodium metaphosphate Nutrition 0.000 description 13
- 229960005066 trisodium edetate Drugs 0.000 description 13
- VBICKXHEKHSIBG-UHFFFAOYSA-N beta-monoglyceryl stearate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 12
- 239000003205 fragrance Substances 0.000 description 12
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 12
- 239000003921 oil Substances 0.000 description 12
- 229920000642 polymer Polymers 0.000 description 12
- 239000002202 Polyethylene glycol Substances 0.000 description 11
- 229940057995 liquid paraffin Drugs 0.000 description 11
- 235000019198 oils Nutrition 0.000 description 11
- 229920001223 polyethylene glycol Polymers 0.000 description 11
- 229920001296 polysiloxane Polymers 0.000 description 11
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 10
- 239000006210 lotion Substances 0.000 description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 10
- 235000013599 spices Nutrition 0.000 description 10
- 229940099259 vaseline Drugs 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 229920001577 copolymer Polymers 0.000 description 9
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 235000021355 Stearic acid Nutrition 0.000 description 8
- 125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 8
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 239000008117 stearic acid Substances 0.000 description 8
- 239000000230 xanthan gum Substances 0.000 description 8
- 235000010493 xanthan gum Nutrition 0.000 description 8
- 229920001285 xanthan gum Polymers 0.000 description 8
- 229940082509 xanthan gum Drugs 0.000 description 8
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 7
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 7
- 229920002125 Sokalan® Polymers 0.000 description 7
- 229940024606 amino acid Drugs 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 7
- 229960005323 phenoxyethanol Drugs 0.000 description 7
- 239000011591 potassium Substances 0.000 description 7
- 229910052700 potassium Inorganic materials 0.000 description 7
- ASKIVFGGGGIGKH-UHFFFAOYSA-N 2,3-dihydroxypropyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(O)CO ASKIVFGGGGIGKH-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 6
- 239000004166 Lanolin Substances 0.000 description 6
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 6
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 6
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 239000004359 castor oil Substances 0.000 description 6
- 235000019438 castor oil Nutrition 0.000 description 6
- 239000011928 denatured alcohol Substances 0.000 description 6
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 6
- XJNUECKWDBNFJV-UHFFFAOYSA-N hexadecyl 2-ethylhexanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)C(CC)CCCC XJNUECKWDBNFJV-UHFFFAOYSA-N 0.000 description 6
- 235000019388 lanolin Nutrition 0.000 description 6
- 229940039717 lanolin Drugs 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 235000018330 Macadamia integrifolia Nutrition 0.000 description 5
- 240000000912 Macadamia tetraphylla Species 0.000 description 5
- 235000003800 Macadamia tetraphylla Nutrition 0.000 description 5
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 5
- XKMYWNHZAQUEPY-YZGJEOKZSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] 12-hydroxyoctadecanoate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCCCCC(O)CCCCCC)C1 XKMYWNHZAQUEPY-YZGJEOKZSA-N 0.000 description 5
- 229940072107 ascorbate Drugs 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 229940072104 cholesteryl hydroxystearate Drugs 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 235000013399 edible fruits Nutrition 0.000 description 5
- 239000010466 nut oil Substances 0.000 description 5
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
- 235000013871 bee wax Nutrition 0.000 description 4
- 239000012166 beeswax Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 229940075507 glyceryl monostearate Drugs 0.000 description 4
- 150000002430 hydrocarbons Chemical group 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 229940119170 jojoba wax Drugs 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 4
- 229940055577 oleyl alcohol Drugs 0.000 description 4
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 4
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 description 4
- 235000019982 sodium hexametaphosphate Nutrition 0.000 description 4
- 239000002689 soil Substances 0.000 description 4
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 4
- 229920002554 vinyl polymer Polymers 0.000 description 4
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 3
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- 241000557626 Corvus corax Species 0.000 description 3
- 150000000996 L-ascorbic acids Chemical class 0.000 description 3
- 244000165082 Lavanda vera Species 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- 150000005690 diesters Chemical class 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 3
- 229940074052 glyceryl isostearate Drugs 0.000 description 3
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 3
- 239000000171 lavandula angustifolia l. flower oil Substances 0.000 description 3
- 229960004857 mitomycin Drugs 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 229960001295 tocopherol Drugs 0.000 description 3
- 239000011732 tocopherol Substances 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- XEFAJZOBODPHBG-UHFFFAOYSA-N 1-phenoxyethanol Chemical compound CC(O)OC1=CC=CC=C1 XEFAJZOBODPHBG-UHFFFAOYSA-N 0.000 description 2
- HMFKFHLTUCJZJO-UHFFFAOYSA-N 2-{2-[3,4-bis(2-hydroxyethoxy)oxolan-2-yl]-2-(2-hydroxyethoxy)ethoxy}ethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCOCC(OCCO)C1OCC(OCCO)C1OCCO HMFKFHLTUCJZJO-UHFFFAOYSA-N 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- 241000132016 Baccharis Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical class C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical group CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- DRRMRHKHTQRWMB-UHFFFAOYSA-N [3-(2-ethylhexanoyloxy)-2,2-bis(2-ethylhexanoyloxymethyl)propyl] 2-ethylhexanoate Chemical compound CCCCC(CC)C(=O)OCC(COC(=O)C(CC)CCCC)(COC(=O)C(CC)CCCC)COC(=O)C(CC)CCCC DRRMRHKHTQRWMB-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 229940082500 cetostearyl alcohol Drugs 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- REZZEXDLIUJMMS-UHFFFAOYSA-M dimethyldioctadecylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC REZZEXDLIUJMMS-UHFFFAOYSA-M 0.000 description 2
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 2
- 239000004664 distearyldimethylammonium chloride (DHTDMAC) Substances 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- 230000037336 dry skin Effects 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 230000036074 healthy skin Effects 0.000 description 2
- 239000012676 herbal extract Substances 0.000 description 2
- ZTVZLYBCZNMWCF-UHFFFAOYSA-N homocystine Chemical compound [O-]C(=O)C([NH3+])CCSSCCC([NH3+])C([O-])=O ZTVZLYBCZNMWCF-UHFFFAOYSA-N 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 2
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 125000006353 oxyethylene group Chemical group 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 229940073490 sodium glutamate Drugs 0.000 description 2
- 229940010747 sodium hyaluronate Drugs 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- DBSABEYSGXPBTA-RXSVEWSESA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O DBSABEYSGXPBTA-RXSVEWSESA-N 0.000 description 1
- CGFPNELNAZZYQL-RXSVEWSESA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;sulfuric acid Chemical compound OS(O)(=O)=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CGFPNELNAZZYQL-RXSVEWSESA-N 0.000 description 1
- DWMGLUVISSMERV-BBIVZNJYSA-N (2r)-2-[(1s)-2-[dihydroxy(methyl)silyl]oxy-1-hydroxyethyl]-3,4-dihydroxy-2h-furan-5-one Chemical compound C[Si](O)(O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O DWMGLUVISSMERV-BBIVZNJYSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- HOVAGTYPODGVJG-UVSYOFPXSA-N (3s,5r)-2-(hydroxymethyl)-6-methoxyoxane-3,4,5-triol Chemical compound COC1OC(CO)[C@@H](O)C(O)[C@H]1O HOVAGTYPODGVJG-UVSYOFPXSA-N 0.000 description 1
- GYPCWHHQAVLMKO-XXKQIVDLSA-N (7s,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-[(e)-n-[(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-ylidene)amino]-c-methylcarbonimidoyl]-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical group Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\N=C1CC(C)(C)N(O)C(C)(C)C1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 GYPCWHHQAVLMKO-XXKQIVDLSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- CRBBOOXGHMTWOC-NPDDRXJXSA-N 1,4-Anhydro-6-O-dodecanoyl-2,3-bis-O-(2-hydroxyethyl)-D-glucitol Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](OCCO)[C@H]1OCCO CRBBOOXGHMTWOC-NPDDRXJXSA-N 0.000 description 1
- OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- URDCARMUOSMFFI-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(2-hydroxyethyl)amino]acetic acid Chemical compound OCCN(CC(O)=O)CCN(CC(O)=O)CC(O)=O URDCARMUOSMFFI-UHFFFAOYSA-N 0.000 description 1
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- IHCCLXNEEPMSIO-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 IHCCLXNEEPMSIO-UHFFFAOYSA-N 0.000 description 1
- OUCGLXKNITVPJS-OUKQBFOZSA-N 2-ethylhexyl (e)-3-phenylprop-2-enoate Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=CC=C1 OUCGLXKNITVPJS-OUKQBFOZSA-N 0.000 description 1
- OQUFOZNPBIIJTN-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;sodium Chemical compound [Na].OC(=O)CC(O)(C(O)=O)CC(O)=O OQUFOZNPBIIJTN-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- XBKONSCREBSMCS-REOHCLBHSA-N 3-disulfanyl-L-alanine Chemical compound OC(=O)[C@@H](N)CSS XBKONSCREBSMCS-REOHCLBHSA-N 0.000 description 1
- ADVPTQAUNPRNPO-REOHCLBHSA-N 3-sulfino-L-alanine Chemical compound OC(=O)[C@@H](N)C[S@@](O)=O ADVPTQAUNPRNPO-REOHCLBHSA-N 0.000 description 1
- WNCMPPNSRXERQI-UHFFFAOYSA-N 4-(3-morpholin-4-ylpyridazin-4-yl)morpholine Chemical compound C1COCCN1C1=CC=NN=C1N1CCOCC1 WNCMPPNSRXERQI-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-M 9-cis,12-cis-Octadecadienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC([O-])=O OYHQOLUKZRVURQ-HZJYTTRNSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 239000004261 Ascorbyl stearate Substances 0.000 description 1
- LITUBCVUXPBCGA-WMZHIEFXSA-N Ascorbyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O LITUBCVUXPBCGA-WMZHIEFXSA-N 0.000 description 1
- 208000012657 Atopic disease Diseases 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 1
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 241000208421 Ericaceae Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- PVNIQBQSYATKKL-UHFFFAOYSA-N Glycerol trihexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 235000002997 Lavandula Nutrition 0.000 description 1
- 241000234435 Lilium Species 0.000 description 1
- 240000000894 Lupinus albus Species 0.000 description 1
- 235000010649 Lupinus albus Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 241000218657 Picea Species 0.000 description 1
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000736246 Pyrola Species 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 229920002197 Sodium polyaspartate Polymers 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 101100068489 Vicia faba AGPC gene Proteins 0.000 description 1
- 229930003537 Vitamin B3 Natural products 0.000 description 1
- 206010048218 Xeroderma Diseases 0.000 description 1
- JPBAVLUULZJFFO-JENHRLMUSA-N [(2s)-2-[(2r)-3,4-dihydroxy-5-oxo-2h-furan-2-yl]-2-hydroxyethyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O JPBAVLUULZJFFO-JENHRLMUSA-N 0.000 description 1
- ZBACKBRRIQPKDN-WMZHIEFXSA-N [(2s)-2-[(2r)-3,4-dihydroxy-5-oxo-2h-furan-2-yl]-2-hydroxyethyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O ZBACKBRRIQPKDN-WMZHIEFXSA-N 0.000 description 1
- MSKSZMDNKAEBSG-HNAYVOBHSA-N [(2s)-2-[(2r)-3,4-dihydroxy-5-oxo-2h-furan-2-yl]-2-hydroxyethyl] tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O MSKSZMDNKAEBSG-HNAYVOBHSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- HDTRYLNUVZCQOY-BTLHAWITSA-N alpha,beta-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-BTLHAWITSA-N 0.000 description 1
- ADVPTQAUNPRNPO-UHFFFAOYSA-N alpha-amino-beta-sulfino-propionic acid Natural products OC(=O)C(N)CS(O)=O ADVPTQAUNPRNPO-UHFFFAOYSA-N 0.000 description 1
- NFCAZOWCMBMODO-UHFFFAOYSA-N alumane;magnesium Chemical compound [Mg].[Mg].[Mg].[AlH3] NFCAZOWCMBMODO-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- KQZNFGJQTPAURD-NBWQQBAWSA-N ascorbyl dipalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](OC(=O)CCCCCCCCCCCCCCC)[C@H]1OC(=O)C(O)=C1O KQZNFGJQTPAURD-NBWQQBAWSA-N 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 229940071097 ascorbyl phosphate Drugs 0.000 description 1
- 235000019276 ascorbyl stearate Nutrition 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- GZSSFSARCMSPPW-UHFFFAOYSA-N butane-2,2-diol Chemical compound CCC(C)(O)O GZSSFSARCMSPPW-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- SHZIWNPUGXLXDT-UHFFFAOYSA-N caproic acid ethyl ester Natural products CCCCCC(=O)OCC SHZIWNPUGXLXDT-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 210000001268 chyle Anatomy 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 150000001923 cyclic compounds Chemical class 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- DTPCFIHYWYONMD-UHFFFAOYSA-N decaethylene glycol Polymers OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO DTPCFIHYWYONMD-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- UFNVPOGXISZXJD-JBQZKEIOSA-N eribulin Chemical compound C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 UFNVPOGXISZXJD-JBQZKEIOSA-N 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 239000010696 ester oil Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 229940072117 fennel extract Drugs 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 239000010437 gem Substances 0.000 description 1
- 229910001751 gemstone Inorganic materials 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 229940118951 halaven Drugs 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- SDPBXXCJVDQPIQ-UHFFFAOYSA-N hexadecyl hexanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCC SDPBXXCJVDQPIQ-UHFFFAOYSA-N 0.000 description 1
- DWMMZQMXUWUJME-UHFFFAOYSA-N hexadecyl octanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCC DWMMZQMXUWUJME-UHFFFAOYSA-N 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- CFSSWEQYBLCBLH-UHFFFAOYSA-N iso-hexadecyl alcohol Natural products CC(C)CCCCCCCCCCCCCO CFSSWEQYBLCBLH-UHFFFAOYSA-N 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 108010075526 keratohyalin Proteins 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940049918 linoleate Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229940074358 magnesium ascorbate Drugs 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- AIOKQVJVNPDJKA-ZZMNMWMASA-L magnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2h-furan-3-olate Chemical compound [Mg+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] AIOKQVJVNPDJKA-ZZMNMWMASA-L 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- HOVAGTYPODGVJG-UHFFFAOYSA-N methyl beta-galactoside Natural products COC1OC(CO)C(O)C(O)C1O HOVAGTYPODGVJG-UHFFFAOYSA-N 0.000 description 1
- 229940095136 methylsilanol ascorbate Drugs 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- WNIFXKPDILJURQ-JKPOUOEOSA-N octadecyl (2s,4as,6ar,6as,6br,8ar,10s,12as,14br)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1h-picene-2-carboxylate Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@](C(=O)OCCCCCCCCCCCCCCCCCC)(C)C[C@H]5C4=CC(=O)[C@@H]3[C@]21C WNIFXKPDILJURQ-JKPOUOEOSA-N 0.000 description 1
- HMMGMWAXVFQUOA-UHFFFAOYSA-N octamethylcyclotetrasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 HMMGMWAXVFQUOA-UHFFFAOYSA-N 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- AFDXODALSZRGIH-UHFFFAOYSA-N p-coumaric acid methyl ether Natural products COC1=CC=C(C=CC(O)=O)C=C1 AFDXODALSZRGIH-UHFFFAOYSA-N 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- QVLTXCYWHPZMCA-UHFFFAOYSA-N po4-po4 Chemical compound OP(O)(O)=O.OP(O)(O)=O QVLTXCYWHPZMCA-UHFFFAOYSA-N 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 239000010670 sage oil Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 230000021148 sequestering of metal ion Effects 0.000 description 1
- 229920002050 silicone resin Polymers 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- VUYXVWGKCKTUMF-UHFFFAOYSA-N tetratriacontaethylene glycol monomethyl ether Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO VUYXVWGKCKTUMF-UHFFFAOYSA-N 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 239000002569 water oil cream Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- LTBBHPKPFHCPTL-UHFFFAOYSA-L zinc;carbonotrithioate Chemical compound [Zn+2].[S-]C([S-])=S LTBBHPKPFHCPTL-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
- A61Q1/02—Preparations containing skin colorants, e.g. pigments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/70—Biological properties of the composition as a whole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to cosmetic or dermatological preparations for controlling or repairing skin damage (or rough skin) due to drying, and to a method for evaluating substances contained in such preparations.
- NMF The natural moisturizing factor
- stratum corneum Blank I.H.J.I. Dermatol., 18, 433 (1952), Blank I.H.J.I. Dermatol., 21, 259 (1953)
- amino acids which are the main components of NMF, are produced by the degradation of filadarin protein derived from keratohyalin granules (Scott IR et al. Biochem Biophys. Acta., 719, 110-117 ( 1982), Horii I. et al., J. Dermatol., 10, 25-33 (1983)).
- Filadharin is a protein consisting of 317 amino acids.
- FR2 777 185-A1 includes a composition for treating cysts that combines a substance that stimulates filadalin synthesis with other active substances to favor regulation of water retention.
- a composition for treating cysts that combines a substance that stimulates filadalin synthesis with other active substances to favor regulation of water retention.
- Japanese Patent Application Laid-Open No. 2000-26272 discloses white rubin [or white lupine (Lupii ⁇ u [salbus)] has been reported to have an effect of increasing the mRNA of filaggrin in keratinocytes of humans and increasing the thickness of the stratum corneum.
- WO99 / 47117 contains a composition containing a vitamin B3 compound that acts as a humectant and increases the level of skin proteins selected from filaggrin, keratin and invocrine, It is stated that the adsorption to the layer or the absorption capacity is enhanced.
- the present inventors have studied the factors involved in drying and horny layer water content in human keratinocytes, and found that drying reduces the levels of filadarin protein and the expression of the gene.
- the present invention is based on this finding.
- a substance capable of significantly suppressing a decrease in filaggrin gene expression ability due to gas phase exposure of cultured human keratinocytes is sufficient in amount to suppress a decrease in the barrier function of the stratum corneum in human skin,
- a skin external preparation comprising a base or an additive acceptable for use in cosmetics and Z or dermatological preparations.
- the substance capable of significantly suppressing the decrease in the expression ability of filaggrin gene is a group consisting of a betaine compound and a derivative thereof, a polyol and a derivative thereof, a crude drug, and a substance having an antioxidant effect. Chosen from 1 One or more external skin preparations are provided.
- the present invention provides a skin capable of suppressing a decrease in the barrier function and moisturizing function of the stratum corneum in human skin, which is a substance capable of significantly suppressing a decrease in the expression ability of filaggrin gene due to gas phase exposure of cultured human keratinocytes. It also relates to the use for the preparation of external preparations.
- the present invention provides a composition comprising one or more selected from the group consisting of betaine compounds and their derivatives, polyols and their derivatives, crude drugs, and substances having antioxidant activity.
- the present invention also relates to a method for suppressing or repairing skin damage due to drying, which comprises a step of applying to the skin of a mouse.
- FIG. 1 is a graph showing the relative time-dependent change in the level of filadarin protein due to drying (gas phase exposure) of cultured human keratinocytes.
- the average soil SEM value for trial n 4 to 5 is shown. Means that p ⁇ 0.01.
- FIG. 3 is a graph showing the effect of glycerin in suppressing the decrease in filadarin protein level due to drying (gas phase exposure) of cultured human keratinocytes.
- the right side of the paired bar shows an example of culture in the presence of 10% glycerin (the left side is control c ).
- FIG. 5 is a graph having the same meaning as FIG. 4 except that a crude drug is used as a drug.
- the concentration of each drug is 0.0025% of the dry residue concentration.
- n 3, * means ⁇ ⁇ 0.05, ** means 1) ⁇ 0.01, *** means ⁇ ⁇ 0.001.
- FIG. 6 is a graph having the same meaning as in FIG. 4 except that ascorbic acid and daltathione were used as drugs at the respective concentrations of ImM. * Means p ⁇ 0.001 and ** means ⁇ 0.01.
- FIG. 7 shows a daraf having the same meaning as in FIG. 4 except that hypotaurine was used as a drug. * Means ⁇ ⁇ 0.05.
- the ability to significantly reduce the decrease in the expression ability of filaggrin gene due to gas-phase exposure of cultured human keratinocytes means that, when evaluated by the evaluation method described below, a control (containing no test substance). This means that the decrease in the expression ability in the test substance-containing system can be statistically significantly suppressed as compared to the decrease in the expression ability in the system of (1).
- skin injury means various changes and skin troubles that are not observed in healthy skin, such as rough skin, formation of fine wrinkles in the skin, and decreased skin flexibility.
- any of the external preparations, uses and methods according to the present invention are included in the active ingredient as long as the above-mentioned decrease in expression ability can be significantly suppressed.
- specific examples of such active ingredients include betaine compounds and their derivatives, polyols and their derivatives, crude drugs, and substances having an antioxidant effect.
- Betaine compounds and their derivatives are defined as betaine (also referred to as glycine betaine) and its derivatives, as long as they meet the purpose of the present invention. Also, any compound included in the zwitterionic compound of the corresponding sultin (where the carboxyl of betaine is replaced by sulfo) may be used. Representative of such derivatives are saturated or unsaturated hydrocarbon chains in which one to three of the N-methyl groups of glycine betaine may be other branched or of the following formula:
- hydrocarbon chain interrupted by an amide bond represented by (C IntelH 2 n CO NH (CH 2 ) m ⁇ ) (wherein, m and n are independently an integer of 1 to 30)
- the length of the hydrocarbon chain between the quaternary ammonium group and the carboxyl or sulfo group is fluctuating (for example, having 2 to 6 carbon atoms), or betaine remains.
- a polymer having a plurality of groups as pendant groups is exemplified. These may be cyclic compounds. Specific examples of such derivatives include, but are not limited to, those described above, as well as Arpuchi mouth betaine, desilbetaine, lauryl betaine, myristyl betaine, cetyl betaine, stearyl betaine, behenyl betaine, Lauramido propyl betaine, oleamido propyl betaine, no. Lumitami.
- polyols include glycerin, 1,3-propanediol, Methyl-1,3-propanediol, 1,4-butanediol, 1,5-pentanediol, diglycerin, erythritol, dalconic acid, 1,2,6-hexanetriol, inositol, lactitol, maltitol, mannitol, Xylitol etc. Possible. In particular, glycerin, combined use of a sugar alcohol including the xylitol and the preferred.
- “Crude drug” refers to a drug or folk medicine or a material obtained by subjecting a plant-derived material to drying, cutting, crushing, extracting, or the like as a raw material. If it is a plant, it does not matter plant family or genus.
- a Baccharis plant of the family Asteraceae (Compositae), in particular, a crude drug derived from Baccharis geisselloids (carqueja (South America)) )]
- a plant of the genus Achyrocline in particular, a herbal medicine, maceramista [macelamista (South America)], derived from the chyle cliche, ⁇ chyrocline satureoides, and a plant of the genus Achillo chillea (especially A chillea).
- millefolium L. plants of the genus Hymus (Labiatae) of the Labiatae family; in particular, herbal extracts derived from Thymus serphyllum Linne subsp. serphyllum; Genus (Origanum) Plants, especially those derived from Majorana (Origanum majorana L.) Marjoramue kiss, a herbal medicine from the genus Scutellaria (especially Scutellaria baicalensis Georgi), and a herbal medicine from the genus Lavendula (Lavandula), especially a lavender oil from the lavender (Lavandula officinalis); Rosa plants of Rosa ro bur hii, especially herbal medicine Izayobara fruits and Prunus plants, especially Prunus lannesiana (Coir.
- Preferred herbal medicines include, but are not limited to, herbal medicine paloazul, herbal medicine Maseramista and
- the “substance having an antioxidant effect” may be any compound or substance (mixture, composition, etc.) as long as the purpose of the present invention can be achieved without adversely affecting the skin. From the perspective of not affecting the skin, Examples thereof include compounds or substances including those already used or proposed to be used as antioxidants in the field of cosmetics.
- Such compounds include, but are not limited to, ascorbic acid and salts or derivatives thereof.
- the salt or derivative include ascorbic acid derivatives such as magnesium ascorbate, sodium ascorbate and the like, alkyl ascorbate, phosphate ascorbate, sulfate ascorbate and darcoside ascorbate.
- examples of the alkyl ascorbate include ascorbyl palmitate, ascorbyl isopalmitate, ascorbyl dipalmitate, ascorbyl diisopanolemitate, ascorbyl stearate, ascorbyl isostearate, ascorbyl distearate, and ascorbyl myristate.
- Other derivatives include ascorbic acid polypeptide, ascorbyl magnesium phosphate, methylsilanol ascorbate, and ascorbyl phosphate Toco Fuwerirukariumu, etc. can be mentioned.
- tocoprol and its derivatives, and derivatives thereof are not limited to, tocoprol esters such as tocofuryl acetate, tocofuryl linoleate, tocofuryl nicotinate, tocofuryl succinate, and the like;
- tocopherol include ethylene oxide adducts of tocophore.
- sulfur-containing amino acid-containing compounds including sulfur-containing amino acids themselves
- their intermediate metabolites such as acetyl cysteine, methionine, cysteine, homocystine, glutathione, hypotaurine, cysteine sulfinic acid, cysteine acid
- examples include thiocysteine, taurine, gencolic acid, cystationin, S-arylcysteine, lentonin, etyonin and the like.
- hypotaurine is a major organ in many mammals, including humans, It is contained in the heart, brain, liver, etc. In addition, no side effects such as irritation to the skin, itching and rash have been reported, and it is an extremely safe amaminoethyl compound. It is to be noted that hypotaurine can be produced and used from an available thio compound such as cysteine by a generally known method, and a commercially available product can also be used. Accordingly, the present inventors are particularly strongly planning the use of hypotaurine.
- the above-mentioned active ingredient is a combination of the above-mentioned crude drug and another active ingredient, more preferably, palo azul as a crude drug, glycerin and a saccharide having 4 to 6 carbon atoms.
- Mention may be made of combinations of oral azul with glycerin and betaine compounds or derivatives thereof.
- the above pharmaceutical preparations can be prepared according to a method known per se, for example, the method described in Hirokawa Medicinal Plant Encyclopedia, Editor Masao Kijima et al., Published in 1982 by Hirokawa Shoten Co., Ltd. it can.
- the external preparation of the present invention may contain, in addition to the above-mentioned active ingredients, bases or additives commonly used in cosmetics and dermatological preparations, or other active ingredients.
- a betaine compound, a polyol or a substance having an antioxidant effect as an active ingredient is added in an amount of 0.001 to 20% by weight, preferably 0.01%, based on the total weight of the external preparation. It can be up to 1.0% by weight.
- herbal medicines can not be limited because the active ingredient content varies depending on the dosage form, the total production amount per preparations, at .0 0 0 1-2 0% by weight (dry matter basis, from about 5 1 0 _ 7 ⁇ 2 ⁇ 1 0 1 wt%), preferably at 0.0 1 to 1.0 wt% (dry solid basis may be from about 5 x 1 0 5 to 5 1 0 3 by weight.
- dry matter basis from about 5 1 0 _ 7 ⁇ 2 ⁇ 1 0 1 wt%
- dry solid basis may be from about 5 x 1 0 5 to 5 1 0 3 by weight.
- the external preparation of the present invention refers to a substance applied to the skin as a cosmetic, a pharmaceutical, a quasi-drug, and therefore, its dosage form is also an aqueous type, a solubilizing type, an emulsion type, a powder type, a gel type, It can take a wide range of forms, such as ointment, cream, water-oil two-layer system, water-oil-powder three-layer system. That is, basic cosmetics can be widely applied to the above-mentioned various dosage forms in the form of facial cleanser, lotion, milky lotion, cream, jewel, essence (cosmetic), pack, mask and the like. If it is a makeup cosmetic, it can be widely applied to forms such as foundations. Furthermore, it can be widely applied to various ointments and the like as long as they are pharmaceuticals or quasi-drugs.
- the form and form of the external preparation for skin of the present invention are not limited to these forms and forms.
- the base component can be selected according to these dosage forms and forms, and as the base component or additive, water, lower alkanol, liquid oil and fat, solid oil and fat, waxes, ester oil, Hydrocarbon oils, silicone resins, silicones, anionic surfactants, anionic surfactants, cationic surfactants, amphoteric surfactants, nonionic surfactants, lower alcohols, sterols, water soluble Examples include polymers, metal ion sequestering agents, neutralizing agents, pH adjusters, antibacterial agents, fragrances, dyes, and the like.
- the external preparations described above can be applied directly to volunteers to confirm the efficacy, but prior to that, another aspect of the present invention is to determine whether or not skin damage due to drying can be suppressed.
- the human keratinocytes used in such an evaluation method can be any type of human keratinocytes that are capable of significantly discriminating changes in the amount of filaggrin protein and gene expression by culturing in the presence and absence of the test substance. It may be a cell. However, preferably, a cultured cell line consisting of normal cells derived from human foreskin and 3T3 cells (ATCCCRL-1658) derived from a mouse as a feeder layer (supporting cell) can be conveniently used. .
- cell lines can be obtained, for example, by culturing 3T3 cells in a suitable Petri dish according to the method described in Rheinwald et al., Cell 6, 331-134 (1975), and mitomycin C After performing the treatment and forming the feeder cell layer in this way, normal human keratinocytes are seeded on the layer, and for example, 95% empty It can be prepared by culturing in a 5% carbon gas environment at 37 ° C until confluence.
- a system cultured in the absence of the test substance is preferably treated in parallel with a culture performed in the presence of the test substance (test system). Culture is performed under various conditions in the presence, and then the amount of filaggrin protein after gas phase exposure ⁇ the expression level of the filadarin gene is obtained, and these values may be used as controls.
- test substance is preferably added to the test system after the cultured human keratinocytes have reached confluence, and then incubated for a short period of time (for example, 30 minutes).
- Such gas phase exposure of cultured human keratinocytes is preferably carried out after removing the medium, for example, by incubating at 37 ° C. in an environment of 95% air and 5% carbon dioxide. be able to. Such gas phase exposure can usually be completed by about 6 hours.
- the cultured human keratinocytes exposed to the gas phase are subjected to a method known per se for measuring the amount of filaggrin protein or the expression level of the filaggrin gene.
- the degree of efficacy of the test article can be evaluated.
- Such an evaluation method is also useful for screening for a further active substance that can prevent skin damage associated with a decrease in filaggrin in human keratinocytes due to drying.
- Percentages used in the description are by weight unless otherwise specified. ,
- the medium contains DMEM—Ham's F12 (3: 1) with hydrocortisone, cholera enterotoxin, epidermal growth factor, insulin and 10% FBS.
- 3T3 cells were treated with mitomycin C and used as a feeder monolayer (feeder cells).
- Five human normal keratinocyte lxlO cells were seeded on 3T3 cells treated with mitomycin C, and cultured at 37 ° C in a 95% air-15% carbon gas environment until confluence. Gas phase exposure was performed by removing the culture supernatant. Each test sample was added 30 minutes before exposure to the gas phase and cultured at 37 ° C. A control to which no test substance was added was used as a control. Gas phase exposures were performed at 37 ° C for 0-6 hours.
- filaggrin protein or filaggrin protein precursor was quantified by Western blotting. The outline is shown below.
- the extracted protein was electrophoresed by SDS-PAGE, transferred to PDV F membrane, and subjected to antigen-antibody reaction using a mouse monoclonal antibody specific for filaggrin (anti-HUMAN Filaggrin MAb) as the primary antibody.
- an antigen-antibody reaction was performed using a secondary antibody labeled with Horseradish peroxidase or Alkaline phosphatase.
- the measurement was carried out using a coloring method or a chemical coloring method in which an enzymatic reaction was performed using a chromogenic substrate corresponding to the labeling enzyme.
- Band quantification was performed using NIH images (analysis program).
- RNA was extracted from cells exposed to the gas phase for a certain period of time using the AGPC method.
- RT-PCR was performed on these RNAs as described below.
- a primer specific for filaggrin was created based on the filaggrin base sequence reported by McKinley-Grant LJ et al., Proc. Natl. Acad. Sci. USA, 86, 4848-4852 (1989).
- mRNA is converted into cDNA once using reverse transcriptase, converted into type III, and subjected to a polymerase reaction (known reaction) using the above primers to measure filaggrin mRNA. Specified.
- the PCR product was electrophoresed on an agarose gel, and the gel after electrophoresis was immersed in an ethidium bromide solution, and then DNA was measured.
- the DNA band was quantified using NIH images (analysis program). Corrections were made using glyceraldehyde-3-phosphate dehydrogenase (G3PDH).
- FIG. 1 shows the time-dependent changes in the amount of filaggrin protein when human keratinocytes were exposed to the gas phase. From the figure, it is clear that the drying significantly reduces the human keratinocyte filaggrin protein.
- FIG. 2 shows the temporal change in the expression level of the filadarin gene in human keratinocytes due to the above gas phase exposure. From the figure, it is clear that the drying significantly reduces the expression of the human keratinocyte filaggrin gene. The decline has occurred within a relatively short time.
- the gene expression before drying is set to 100%, and the gene expression after drying is set to 0%, and the suppression rate of the decrease in gene expression due to the addition of the drug is shown in%.
- 0.5% of the active ingredient was added as an extract concentration.
- Table 2 the composition was tested using the active ingredient and concentration (% by weight) indicated therein. ⁇
- the above recovery rate (%) indicates the extent to which the test substance was restored to the filaggrin gene expression level in the untreated group to which no drying stimulus was applied, respectively.
- the preparation according to the present invention reduces the water content of the stratum corneum due to drying of human keratinocytes, the protein content of filaggrin, which is a raw material for amino acids essential for maintaining the water content of the stratum corneum, and gene expression It can be confirmed that the decrease in the temperature can be suppressed significantly.
- Behenyl alcohol 1.0 Stearyl alcohol 2.0 Squalane 1 0.0 Pentaerythyl tetraoctanoate 5.0 Lanolin 5.0 Paraben 0.3 Polyoxyethylene behenyl alcohol 1.0 Glycerin 1 0.0 Crude drug extract (crude carqueja) 0.2 Sodium acetylhyaluronate 0.1 Purified water Formulation example 2 (cream)
- Cetostearyl alcohol 3.5 Squalane 20.0 Beeswax 3.0 Lanolin 5.0 Paraben 0.3 Polyoxyethylene (20) sonobitan monopalmitate 2.0 Stearate monoglyceride 2.0 Plant extract (herbal medicine Palo azul) 2.0 Vitamin A 2.0 Flavor
- Liquid paraffin 5.0 Vaseline 2.0 Methylpolysiloxane 1.0 Stearyl alcohol 2.0 Behenyl alcohol 2.0 Hardened oil 1.0 Squalane 5.0 Stearic acid 2.0
- Methylpolysiloxane 2.0 Decamethylcyclopentasiloxane 0.0 Polyoxethylene / methylpolysiloxane polymer 3.0 Citrate to dimethyldistearylammonium 3.0 Denatured alcohol prescribed by government 2.0 Glycerin 5. 0 Dipropylene glycol 3.0 Polyethylene glycol 1.0 Sodium metaphosphate 0.05 Plant extract (herbal medicine palo azul) 2.0 Plant extract (herbal medicine Sakura leaf extract) 1.0 Paraben
- Methyl ⁇ polysiloxane 5.0 Decamethylcyclopentylsiloxane 10.0 Polyoxyxylene / methylpolysiloxane copolymer 0.5 Poly (oxyethylene.oxypropylene)
- Methyl polysiloxane copolymer 0.5 Spherical alkyl polyacrylate 2.0 Glycerin 5.0 Plant extract (herbal medicine palo azul) 0.0 5 Plant extract (herbal medicine SEgon liquid SE) 2.0
- Methylpolysiloxane 5.0 Decamethylcyclopentasiloxane 5.0 Behenyl alcohol 1.0 Styrene bean wax 1.0 Beesham wax 2.0 Glyceryl tri-2-ethylhexanoate 2.0 Cetyl octanoate 2. 0 Glycerin 4.0 Plant extract (herbal medicine palo azul) 0.1 Plant extract (herbal medicine Hamamelis). 0.2 Dipropylenedaricol 6.0 Trisodium edetate 0.05 Paraben
- Vaseline 1.0 Methylpolysiloxane 2.0 Squalane 2.0 Glycerin 5.0 Cypropylenedaricol 3.0
- Olefinoligomer 8.0 Vaseline 5.0 Ceresin 4.0 Squalane 8.0 Beeswax 1.0 Polyglycerol phosphate phosphate 5.0 Serine
- Methylpolysiloxane 2.0 Behenyl alcohol 0.5 Bacyl alcohol 0.5 Hardened oil 3.0 Squalane 6.0 Tetra-2-ethylhexanoic acid pentaerythrite 2.0 Polyoxetylene glyceryl isostearate 1 .5 Polyoxyethylene glycerin monostearate 1.5 Glycerin 5.0 1,3-butylene glycol 5.0 erythritol 3.0 plant extract (herbal medicine palo azul) 0.05 potassium hydroxide 0.05 sodium metaphosphate 0.03 phenoxyethanol
- Vaseline 5.0 Behenenoleanolecole 0.5 Hardened oil 1.5 Jojoba oil 2.5 Squalane 4.0 Pentaerythrate tetraoctanoate 3.0 Polyoxyxylene hardened castor oil 0.5 Glycerin 5.0
- 1,3-butylene glycol 4.0 polyethylene glycol 3.0 palm oil fatty acid hydrolyzed collagen potassium solution 0.2 potassium hydroxide 0.08 trisodium edetate 0.05 xanthan gum 0.05 Polymer 0.2 0.2 Two-color agent
- Cetostearyl alcohol 3.5 Squalane 20.0 Beeswax 3.0 Lanolin 5.0 Paraben 0.3 Polyoxyethylene (20) sonobitan monopalmitate 2.0 Stearic acid monoglyceride 2.0 Hipotaurine 0.1 Vitamin A 2.0 Fragrance
- Cyclomethicone 30 Polyoxyethylene-methylpolysiloxane copolymer 1.5 Glycerin 5 Dipropylenedaricol 5 Xylitol 3 Talc 5 Paraben
- Trimethylsiloxykeic acid 0.5 Spherical gay anhydride 0.5 Fine titanium oxide (hydrophobized product 30 nm) 7 Spherical polyethylene powder 2 Poly (oxyethylene'oxypropylene) *
- Liquid paraffin 7 Vaseline 3 Decamethylcyclopentasiloxane 2 Behenylanolecole 2 Glycerin 5 Dipropylene dalicol 7 Polyethylene glycol 1 500 0 2 Xylitol 2 Jojoba oil
- Isostearic acid 0.5 Stearic acid 0.5 Behenic acid 0.5 Pentaerythrit tetra-2-ethylhexanoate 3 Cetyl 2-ethylhexanoate 3 Glycerin monostearate 1 Polyoxyethylene glyceryl monostearate
- Methyl polysiloxane 2 Behenyl alcohol 1 Bacyl alcohol 0.5 Glycerin 5
- 1,3-butylene glycol 7 xylitol 2 erythritol 2 hydrogenated oil 3 squalane 6 tetra-2-ethylhexanoate pentaerythrit 2 polyoxoxylene glyceryl isostearate
- Decamethylcyclopentasiloxane 1 5 Trimethylsiloxygeic acid 5
- Methylpolysiloxane 3 Decamethylcyclopentasiloxane 4 Ethyl alcohol 5 Glycerin 6
- Vaseline 5 Behenenorea noreco 0.4 Bacyl alcohol 0.4 Glycerin 7
- 1,3-butylene glycol 7 xylitol 3 Polyethylene glycol 2 0 0 0 0 2 Hardened oil 2 Jojoba oil 2 Squalane 5 Isostearate 0.4 Tetra-2-ethylhexanoic acid pentaerythritol 2 Polyoxetylene hardened castor oil 0.5 Lauryl dimethylamino acetate betaine 0 .4 Potassium hydroxide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Birds (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002554078A JP3782779B2 (ja) | 2000-12-28 | 2001-12-28 | 皮膚外用剤 |
KR10-2003-7008784A KR20030074690A (ko) | 2000-12-28 | 2001-12-28 | 건조에 의한 피부 상해의 억제제 또는 회복제 및 이들의평가방법 |
US10/465,912 US20040044077A1 (en) | 2000-12-28 | 2001-12-28 | Agents for inhibiting or restoring skin damage caused by drying and method for evaluating the same |
EP01995033A EP1354580A1 (en) | 2000-12-28 | 2001-12-28 | Agents for inhibiting or restoring skin damage caused by drying and method of evaluating the same |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000-402005 | 2000-12-28 | ||
JP2000-402085 | 2000-12-28 | ||
JP2000402005 | 2000-12-28 | ||
JP2000402085 | 2000-12-28 | ||
JP2001-108422 | 2001-04-06 | ||
JP2001108422 | 2001-04-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002053127A1 true WO2002053127A1 (fr) | 2002-07-11 |
Family
ID=27345626
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/011615 WO2002053127A1 (fr) | 2000-12-28 | 2001-12-28 | Agents d'inhibition ou de reparation d'affections cutanees causees par la secheresse, et procede d'evaluation de celles-ci |
Country Status (7)
Country | Link |
---|---|
US (1) | US20040044077A1 (ja) |
EP (1) | EP1354580A1 (ja) |
JP (1) | JP3782779B2 (ja) |
KR (1) | KR20030074690A (ja) |
CN (1) | CN1294896C (ja) |
TW (1) | TW200509983A (ja) |
WO (1) | WO2002053127A1 (ja) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1475097A2 (en) * | 2003-05-08 | 2004-11-10 | Dajas Mendez, José Federico | Dermatological compositions comprising an extract of achyrocline sp (marcela), uses and process for the preparation thereof |
JP2005213170A (ja) * | 2004-01-28 | 2005-08-11 | Hosokawa Funtai Gijutsu Kenkyusho:Kk | ナノ粒子含有組成物およびその製造方法 |
JP2005239645A (ja) * | 2004-02-27 | 2005-09-08 | Rohto Pharmaceut Co Ltd | コラーゲン合成促進用組成物 |
JP2006016337A (ja) * | 2004-07-01 | 2006-01-19 | Maruzen Pharmaceut Co Ltd | フィラグリン産生促進剤及び皮膚化粧料 |
JP2006111630A (ja) * | 2004-10-18 | 2006-04-27 | Amorepacific Corp | 皮膚保湿用化粧料組成物 |
JP2007277149A (ja) * | 2006-04-06 | 2007-10-25 | Kao Corp | インボルクリン発現促進剤 |
WO2008114732A1 (ja) * | 2007-03-16 | 2008-09-25 | Shiseido Company Ltd. | しわ防止・改善剤 |
JP2009215298A (ja) * | 2008-03-11 | 2009-09-24 | L'oreal Sa | アスコルビン酸またはサリチル酸化合物を含む化粧用組成物 |
JP2009256269A (ja) * | 2008-04-18 | 2009-11-05 | Tsumura Lifescience Co Ltd | プロフィラグリン及び/又はフィラグリン産生促進剤 |
JP2010248211A (ja) * | 2010-06-10 | 2010-11-04 | Rohto Pharmaceut Co Ltd | コラーゲン合成促進用組成物 |
JP2012121920A (ja) * | 2003-12-23 | 2012-06-28 | Thorel Jean Noel | 生体適合性のガレン基剤の無害製剤方法 |
WO2014024518A1 (ja) * | 2012-08-10 | 2014-02-13 | 株式会社資生堂 | フィラグリン遺伝子発現促進剤 |
JP2014166964A (ja) * | 2013-02-28 | 2014-09-11 | Club Cosmetics Co Ltd | フィラグリン発現促進剤およびそれを用いた化粧品、皮膚外用剤 |
JP2016172710A (ja) * | 2015-03-18 | 2016-09-29 | ほまれ酒造株式会社 | 化粧料 |
JP2018172328A (ja) * | 2017-03-31 | 2018-11-08 | 株式会社Cac | 皮膚バリア増強剤、医薬組成物、薬用化粧品、及び美容方法 |
JP7460134B2 (ja) | 2019-05-23 | 2024-04-02 | ポーラ化成工業株式会社 | デスモグレイン減少剤 |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002265347A (ja) * | 2001-03-13 | 2002-09-18 | Shiseido Co Ltd | コーニファイドエンベロープの成熟を促す化粧料 |
DE10356164A1 (de) * | 2003-12-02 | 2005-08-04 | Beiersdorf Ag | Wirkstoffkombinationen aus Licochalcon A oder einem Extrakt aus Radix Clycyrrhizae inflatae, enthaltend Licochalcon A, Phenoxyethanol und gewünschtenfalls Glycerin |
FR2863165B1 (fr) * | 2003-12-05 | 2006-04-07 | Silab Sa | Procede d'obtention d'un principe actif a partir de baccharis a activite cosmetique anti-age, principe actif et composition cosmetique obtenue |
JP4526839B2 (ja) * | 2004-03-05 | 2010-08-18 | 株式会社資生堂 | 角層中の酸化タンパク質を指標とする角層の透明性・保水性を評価する方法 |
US10183076B2 (en) | 2005-05-16 | 2019-01-22 | Resdevco Research And Development Co. L | Topical compositions for treatment of irritation of mucous membranes |
IL168603A (en) * | 2005-05-16 | 2011-05-31 | Resdevco Res And Dev Co | Pharmaceutical or cosmetic composition for the prevention and treatment of irritation of mucous cells or skin cells |
FR2892635B1 (fr) * | 2005-10-28 | 2012-11-09 | Engelhard Lyon | Substance pour restaurer une co-expression et une interaction normales entre les proteines lox et nrage |
KR100722675B1 (ko) * | 2005-12-27 | 2007-05-29 | 주식회사 코리아나화장품 | 글루콘산 및 헥사노일트리펩타이드를 유효성분으로함유하는 피부 각질 제거용 화장료 조성물 |
US20080279968A1 (en) * | 2007-05-10 | 2008-11-13 | Marvin Heuer | Composition and method for inducing lipolysis and increasing the metabolism of free fatty acids |
US20080279967A1 (en) * | 2007-05-10 | 2008-11-13 | Marvin Heuer | Composition and method for increasing the metabolism of free fatty acids and facilitating a favorable blood lipid |
KR100888743B1 (ko) * | 2007-09-11 | 2009-03-17 | 재단법인 제주하이테크산업진흥원 | 조록나무 추출물을 유효성분으로 함유하는 항산화, 미백 및피부주름생성억제효과를 갖는 화장료조성물 |
KR100878026B1 (ko) * | 2007-09-12 | 2009-01-20 | (주)더페이스샵코리아 | 나노리포좀으로 안정화된 백리향 추출물을 함유하는 피부보습용 화장료 조성물 |
KR100918616B1 (ko) | 2007-10-24 | 2009-09-25 | 한국과학기술연구원 | 오틸리아 추출물을 유효성분으로 함유하는 조성물 |
US20170354624A1 (en) * | 2007-11-14 | 2017-12-14 | Resdevco Research And Development Co. Ltd. | Topical compositions for treatment of skin irritation |
KR101538468B1 (ko) * | 2008-11-18 | 2015-07-23 | (주)아모레퍼시픽 | 7,3',4'-트리하이드록시이소플라본을 함유하는 피부 장벽 강화용 또는 보습용 피부 외용제 조성물 |
JP6009147B2 (ja) * | 2011-03-15 | 2016-10-19 | 株式会社 資生堂 | ブレオマイシン水解酵素産生促進剤 |
KR102101810B1 (ko) * | 2012-06-11 | 2020-04-20 | (주)아모레퍼시픽 | 항노화 화장료 조성물 |
CN112004516B (zh) * | 2018-03-29 | 2024-03-12 | 株式会社Lg生活健康 | 皮肤屏障功能异常的改善用组合物 |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4639358B1 (ja) * | 1968-10-04 | 1971-11-19 | ||
JPH01275511A (ja) * | 1988-04-26 | 1989-11-06 | Shiseido Co Ltd | 肌荒れ防止剤および老化防止剤 |
JPH03275610A (ja) * | 1990-03-23 | 1991-12-06 | Kyowa Hakko Kogyo Co Ltd | 化粧水 |
JPH06293625A (ja) * | 1993-04-08 | 1994-10-21 | Asahi Chem Ind Co Ltd | 化粧水 |
JPH06293624A (ja) * | 1993-04-08 | 1994-10-21 | Asahi Chem Ind Co Ltd | 乳化型化粧品 |
JPH08119869A (ja) * | 1994-10-26 | 1996-05-14 | Mikimoto Pharmaceut Co Ltd | 活性酸素抑制剤 |
JPH092935A (ja) * | 1995-06-19 | 1997-01-07 | Tsumura & Co | 浴用剤組成物及びその使用方法 |
JPH0995414A (ja) * | 1995-09-29 | 1997-04-08 | Shiseido Co Ltd | 皮膚外用剤 |
JPH11171757A (ja) * | 1997-12-11 | 1999-06-29 | Shiseido Co Ltd | 皮膚外用剤 |
EP0943324A2 (en) * | 1998-03-17 | 1999-09-22 | Shiseido Company, Ltd. | External skin treatment composition |
EP0953341A2 (en) * | 1998-02-24 | 1999-11-03 | Shiseido Company, Ltd. | Antiplasmin agent |
JP2000247825A (ja) * | 1999-02-23 | 2000-09-12 | Nippon Fine Chem Co Ltd | 化粧料および外用剤 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020103137A1 (en) * | 1997-03-30 | 2002-08-01 | Shiseido Co., Ltd. | Method of treating environmental stress |
-
2001
- 2001-12-28 US US10/465,912 patent/US20040044077A1/en not_active Abandoned
- 2001-12-28 WO PCT/JP2001/011615 patent/WO2002053127A1/ja not_active Application Discontinuation
- 2001-12-28 TW TW093136541A patent/TW200509983A/zh unknown
- 2001-12-28 KR KR10-2003-7008784A patent/KR20030074690A/ko not_active Application Discontinuation
- 2001-12-28 JP JP2002554078A patent/JP3782779B2/ja not_active Expired - Lifetime
- 2001-12-28 CN CNB018216110A patent/CN1294896C/zh not_active Withdrawn - After Issue
- 2001-12-28 EP EP01995033A patent/EP1354580A1/en not_active Withdrawn
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4639358B1 (ja) * | 1968-10-04 | 1971-11-19 | ||
JPH01275511A (ja) * | 1988-04-26 | 1989-11-06 | Shiseido Co Ltd | 肌荒れ防止剤および老化防止剤 |
JPH03275610A (ja) * | 1990-03-23 | 1991-12-06 | Kyowa Hakko Kogyo Co Ltd | 化粧水 |
JPH06293625A (ja) * | 1993-04-08 | 1994-10-21 | Asahi Chem Ind Co Ltd | 化粧水 |
JPH06293624A (ja) * | 1993-04-08 | 1994-10-21 | Asahi Chem Ind Co Ltd | 乳化型化粧品 |
JPH08119869A (ja) * | 1994-10-26 | 1996-05-14 | Mikimoto Pharmaceut Co Ltd | 活性酸素抑制剤 |
JPH092935A (ja) * | 1995-06-19 | 1997-01-07 | Tsumura & Co | 浴用剤組成物及びその使用方法 |
JPH0995414A (ja) * | 1995-09-29 | 1997-04-08 | Shiseido Co Ltd | 皮膚外用剤 |
JPH11171757A (ja) * | 1997-12-11 | 1999-06-29 | Shiseido Co Ltd | 皮膚外用剤 |
EP0953341A2 (en) * | 1998-02-24 | 1999-11-03 | Shiseido Company, Ltd. | Antiplasmin agent |
EP0943324A2 (en) * | 1998-03-17 | 1999-09-22 | Shiseido Company, Ltd. | External skin treatment composition |
JP2000247825A (ja) * | 1999-02-23 | 2000-09-12 | Nippon Fine Chem Co Ltd | 化粧料および外用剤 |
Non-Patent Citations (2)
Title |
---|
TOKUJI SEGUCHI ET AL.: "Decreased expression of filaggrin in atopic skin", ARCH. DERMATOL. RES., vol. 288, 1996, pages 442 - 446, XP002950708 * |
TOKUJI SEGUCHI: "Atopy-sei hifu-en kanja hifu hyohi no saishu bunka sanbutsu no ijyo ni tsuite", MED. J. KINKI UNIV., vol. 18, no. 4, 1993, pages 511 - 519, XP002950701 * |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1475097A3 (en) * | 2003-05-08 | 2004-12-01 | Dajas Mendez, José Federico | Dermatological compositions comprising an extract of achyrocline sp (marcela), uses and process for the preparation thereof |
EP1475097A2 (en) * | 2003-05-08 | 2004-11-10 | Dajas Mendez, José Federico | Dermatological compositions comprising an extract of achyrocline sp (marcela), uses and process for the preparation thereof |
JP2012121920A (ja) * | 2003-12-23 | 2012-06-28 | Thorel Jean Noel | 生体適合性のガレン基剤の無害製剤方法 |
JP2005213170A (ja) * | 2004-01-28 | 2005-08-11 | Hosokawa Funtai Gijutsu Kenkyusho:Kk | ナノ粒子含有組成物およびその製造方法 |
JP2005239645A (ja) * | 2004-02-27 | 2005-09-08 | Rohto Pharmaceut Co Ltd | コラーゲン合成促進用組成物 |
JP2006016337A (ja) * | 2004-07-01 | 2006-01-19 | Maruzen Pharmaceut Co Ltd | フィラグリン産生促進剤及び皮膚化粧料 |
JP2006111630A (ja) * | 2004-10-18 | 2006-04-27 | Amorepacific Corp | 皮膚保湿用化粧料組成物 |
JP2007277149A (ja) * | 2006-04-06 | 2007-10-25 | Kao Corp | インボルクリン発現促進剤 |
JP5501758B2 (ja) * | 2007-03-16 | 2014-05-28 | 株式会社 資生堂 | しわ防止・改善剤 |
WO2008114732A1 (ja) * | 2007-03-16 | 2008-09-25 | Shiseido Company Ltd. | しわ防止・改善剤 |
JP2009215298A (ja) * | 2008-03-11 | 2009-09-24 | L'oreal Sa | アスコルビン酸またはサリチル酸化合物を含む化粧用組成物 |
JP2009256269A (ja) * | 2008-04-18 | 2009-11-05 | Tsumura Lifescience Co Ltd | プロフィラグリン及び/又はフィラグリン産生促進剤 |
JP2010248211A (ja) * | 2010-06-10 | 2010-11-04 | Rohto Pharmaceut Co Ltd | コラーゲン合成促進用組成物 |
JP2014055127A (ja) * | 2012-08-10 | 2014-03-27 | Shiseido Co Ltd | フィラグリン遺伝子発現促進剤 |
WO2014024518A1 (ja) * | 2012-08-10 | 2014-02-13 | 株式会社資生堂 | フィラグリン遺伝子発現促進剤 |
US9827187B2 (en) | 2012-08-10 | 2017-11-28 | Shiseido Company, Ltd. | Filaggrin gene expression promoter |
JP2014166964A (ja) * | 2013-02-28 | 2014-09-11 | Club Cosmetics Co Ltd | フィラグリン発現促進剤およびそれを用いた化粧品、皮膚外用剤 |
JP2016172710A (ja) * | 2015-03-18 | 2016-09-29 | ほまれ酒造株式会社 | 化粧料 |
JP2018172328A (ja) * | 2017-03-31 | 2018-11-08 | 株式会社Cac | 皮膚バリア増強剤、医薬組成物、薬用化粧品、及び美容方法 |
JP7460134B2 (ja) | 2019-05-23 | 2024-04-02 | ポーラ化成工業株式会社 | デスモグレイン減少剤 |
Also Published As
Publication number | Publication date |
---|---|
EP1354580A1 (en) | 2003-10-22 |
CN1294896C (zh) | 2007-01-17 |
JPWO2002053127A1 (ja) | 2004-04-30 |
TW200509983A (en) | 2005-03-16 |
KR20030074690A (ko) | 2003-09-19 |
JP3782779B2 (ja) | 2006-06-07 |
US20040044077A1 (en) | 2004-03-04 |
CN1484521A (zh) | 2004-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3782779B2 (ja) | 皮膚外用剤 | |
KR20070003907A (ko) | 혈청 노화 인자 격리 제제 및 이를 위한 용도 | |
FR2880802A1 (fr) | Composition cosmetique ou dermopharmaceutique contenant un extrait d'euglene | |
TW201206494A (en) | Use of Tiliacora triandra in cosmetics and compositions thereof | |
TW200950815A (en) | Composition for external use | |
JP2010138154A (ja) | エージング対応用の皮膚外用剤 | |
JP2003063985A (ja) | N−アシルアミノアミドファミリーのエラスターゼ阻害剤化合物と少なくとも1種の抗炎症剤化合物の組み合わせを含む化粧品用又は皮膚用組成物 | |
JP2008037764A (ja) | 皮脂分泌抑制剤およびニキビ改善用皮膚外用剤 | |
JP2003277223A (ja) | マトリックスメタロプロテアーゼ活性阻害剤および皮膚弾力性維持化粧料。 | |
JP2000136124A (ja) | 皮膚外用剤 | |
WO2012081370A1 (ja) | エンドセリン作用抑制剤及び美白剤 | |
WO2009141543A1 (fr) | Utilisation d'un extrait de baie, et plus particulierement de wolfberry, a titre d'agent anti-pollution | |
JP2008088075A (ja) | プロフィラグリン/フィラグリン産生促進剤、表皮角化細胞増殖促進剤、表皮/角層正常化用皮膚外用剤、プロフィラグリン及び/又はフィラグリン産生促進方法、及び表皮角化細胞増殖促進方法 | |
JP2004175734A (ja) | 皮膚障害抑制剤、皮膚障害改善剤並びにそれらを含有する皮膚外用剤 | |
WO2006101119A1 (ja) | コラーゲン合成促進剤 | |
KR101863297B1 (ko) | 클로로겐산 및 루틴 화합물을 유효성분으로 포함하는 피부 주름 예방 또는 개선용 조성물 | |
JP2000169329A (ja) | 化粧料組成物 | |
JP4413387B2 (ja) | コラーゲン産生促進剤、エラスターゼ活性阻害剤、コラゲナーゼ活性阻害剤及び皮膚化粧料 | |
KR100478033B1 (ko) | 피부주름 형성억제효과를 갖는 조성물 | |
EP1306090A1 (en) | Cosmetics or dermatological preparations containing polymers having phosphorylcholine side chain | |
JP2004168732A (ja) | 活性酸素消去剤、ヒアルロン酸合成促進・分解抑制剤およびアクアポリン合成促進剤 | |
JP2010138153A (ja) | 紫外線予防用の皮膚外用剤 | |
JP2008094734A (ja) | 抗しわ剤および皮膚外用剤 | |
JP2009256269A (ja) | プロフィラグリン及び/又はフィラグリン産生促進剤 | |
FR2885802A1 (fr) | Utilisation cosmetique de la vitamine k pour ameliorer la fonction barriere de la peau |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CN JP KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2002 554078 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10465912 Country of ref document: US Ref document number: 1020037008784 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 018216110 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001995033 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020037008784 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2001995033 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001995033 Country of ref document: EP |